Vor Biopharma Inc. (NYSE:VOR) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Vor Biopharma Inc. (NYSE:VOR) has received a consensus rating of "Moderate Buy" from ten rating firms, with four analysts recommending a hold and six advising a buy.
• The average 12-month target price for VOR among brokerages is $5.63, reflecting a positive outlook despite recent fluctuations in analyst ratings.
• The company operates as a clinical-stage cell and genome engineering firm, with its lead product, tremtelectogene empogeditemcel, currently in phase 1/2 trials for treating acute myeloid leukemia.

Shares of Vor Biopharma Inc. (NYSE:VOR - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten analysts that are covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $5.63.

A number of research firms have issued reports on VOR. Jones Trading downgraded Vor Biopharma from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Citizens Jmp downgraded shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a report on Friday, May 9th. Wedbush reissued an "outperform" rating on shares of Vor Biopharma in a research report on Thursday, June 26th. Baird R W cut Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Finally, HC Wainwright raised Vor Biopharma from a "neutral" rating to a "buy" rating and set a $3.00 price objective on the stock in a research report on Monday, June 30th.

Vor Biopharma Trading Up 1.4%

VOR traded up $0.03 during trading on Wednesday, reaching $2.10. The stock had a trading volume of 2,453,730 shares, compared to its average volume of 8,205,063. The stock's 50 day moving average is $1.22 and its two-hundred day moving average is $1.00. The company has a market capitalization of $262.42 million, a price-to-earnings ratio of -1.27 and a beta of 2.04. Vor Biopharma has a one year low of $0.13 and a one year high of $3.29.

Institutional Investors Weigh In On Vor Biopharma

A number of institutional investors have recently added to or reduced their stakes in VOR. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in shares of Vor Biopharma in the fourth quarter valued at $33,000. Money Concepts Capital Corp lifted its position in shares of Vor Biopharma by 106.1% during the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after purchasing an additional 26,535 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Vor Biopharma during the fourth quarter worth $60,000. Goldman Sachs Group Inc. lifted its position in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after purchasing an additional 58,247 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Vor Biopharma in the fourth quarter valued at about $80,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.